BR112013001125A2 - compostos inibidores de rho cinase bifuncionais, composição e uso - Google Patents
compostos inibidores de rho cinase bifuncionais, composição e usoInfo
- Publication number
- BR112013001125A2 BR112013001125A2 BR112013001125A BR112013001125A BR112013001125A2 BR 112013001125 A2 BR112013001125 A2 BR 112013001125A2 BR 112013001125 A BR112013001125 A BR 112013001125A BR 112013001125 A BR112013001125 A BR 112013001125A BR 112013001125 A2 BR112013001125 A2 BR 112013001125A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- bifunctional
- relates
- kinase inhibiting
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
compostos inibidores de rho cinase bifuncionais, composição e uso. esta invenção refere-se a compostos bifuncionais sintéticos compreendendo um primeiro composto de inibição de cinase associada-rho (rock) e um segundo composto farmaceuticamente ativo com atividade complementar; o primeiro e o segundo compostos são ligados covalentemente por uma ligação biologicamente instável. esta invenção também refere-se a processos de fabricação de tais compostos. a invenção também refere-se a processos de uso de tais compostos bifuncionais na prevenção ou tratamento de doenças ou condições que são afetadas ou podem ser auxiliadas através de alteração de integridade ou rearranjo de citoesqueleto. particularmente, esta invenção refere-se a processos de tratamento de doenças oftálmicas tais como distúrbios nos quais pressão intraocular é elevada, por exemplo, glaucoma de ângulo aberto primário, usando os compostos bifuncionais.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36568110P | 2010-07-19 | 2010-07-19 | |
PCT/US2011/044148 WO2012012282A1 (en) | 2010-07-19 | 2011-07-15 | Bifunctional rho kinase inhibitor compounds, composition and use |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013001125A2 true BR112013001125A2 (pt) | 2016-05-17 |
Family
ID=45497139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013001125A BR112013001125A2 (pt) | 2010-07-19 | 2011-07-15 | compostos inibidores de rho cinase bifuncionais, composição e uso |
Country Status (11)
Country | Link |
---|---|
US (1) | US20130131106A1 (pt) |
EP (1) | EP2595665A1 (pt) |
JP (1) | JP2013531063A (pt) |
KR (1) | KR20130093093A (pt) |
CN (1) | CN103052406A (pt) |
AU (1) | AU2011279909A1 (pt) |
BR (1) | BR112013001125A2 (pt) |
CA (1) | CA2805242A1 (pt) |
MX (1) | MX2013000664A (pt) |
RU (1) | RU2013107007A (pt) |
WO (1) | WO2012012282A1 (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10842669B2 (en) * | 2008-11-13 | 2020-11-24 | Gholam A. Peyman | Ophthalmic drug delivery method |
EA037918B1 (ru) | 2011-12-21 | 2021-06-07 | Новира Терапьютикс, Инк. | Противовирусные агенты против гепатита в |
WO2014033176A1 (en) | 2012-08-28 | 2014-03-06 | Janssen R&D Ireland | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
PT2914590T (pt) * | 2012-10-31 | 2017-02-27 | Ph Pharma Co Ltd | Inibidores de rock |
PT2961732T (pt) | 2013-02-28 | 2017-06-26 | Janssen Sciences Ireland Uc | Sulfamoil-arilamidas e utilização das mesmas como medicamentos para o tratamento de hepatite b |
BR112015025052A2 (pt) | 2013-04-03 | 2021-07-06 | Janssen Sciences Ireland Uc | derivados de n-fenil-carboxamida e o seu uso como medicamentos para o tratamento da hepatite b |
EP2990040B1 (en) | 2013-04-24 | 2019-12-04 | Kyushu University, National University Corporation | Therapeutic agent for eyeground disease |
CA2909742C (en) | 2013-05-17 | 2020-08-04 | Janssen Sciences Ireland Uc | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
SI3024819T1 (en) | 2013-07-25 | 2018-06-29 | Janssen Sciences Ireland Uc | Glyoxamide-substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis B |
UA117261C2 (uk) | 2013-10-23 | 2018-07-10 | ЯНССЕН САЙЄНСЕЗ АЙРЛЕНД ЮСі | Похідні карбоксаміду та їх застосування як медикаментів для лікування гепатиту b |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
JP6553059B2 (ja) | 2014-02-05 | 2019-07-31 | ノヴィラ・セラピューティクス・インコーポレイテッド | Hbv感染の治療のための併用療法 |
MX367689B (es) | 2014-02-06 | 2019-09-02 | Janssen Sciences Ireland Uc | Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
US9884831B2 (en) | 2015-03-19 | 2018-02-06 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis B infections |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
CN108430971A (zh) | 2015-09-29 | 2018-08-21 | 诺维拉治疗公司 | 乙型肝炎抗病毒剂的晶体形式 |
MX2018012557A (es) | 2016-04-15 | 2019-07-04 | Janssen Sciences Ireland Uc | Combinaciones y métodos que comprenden un inhibidor del ensamblaje de la cápside. |
KR102069205B1 (ko) | 2017-08-09 | 2020-01-22 | 연성정밀화학(주) | 라타노프로스틴 부노드의 제조 방법 및 그를 위한 중간체 |
US10973801B2 (en) | 2018-03-14 | 2021-04-13 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
US20210292766A1 (en) | 2018-08-29 | 2021-09-23 | University Of Massachusetts | Inhibition of Protein Kinases to Treat Friedreich Ataxia |
CA3127152A1 (en) | 2019-02-22 | 2020-08-27 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases |
BR112021021454A2 (pt) | 2019-05-06 | 2021-12-21 | Janssen Sciences Ireland Unlimited Co | Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv |
AU2022328634A1 (en) | 2021-08-18 | 2024-02-22 | Chemocentryx, Inc. | Aryl sulfonyl compounds as ccr6 inhibitors |
EP4387609A2 (en) | 2021-08-18 | 2024-06-26 | ChemoCentryx, Inc. | Aryl sulfonyl (hydroxy) piperidines as ccr6 inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990002553A1 (en) * | 1988-09-06 | 1990-03-22 | Pharmacia Ab | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
CN100425241C (zh) * | 2002-08-29 | 2008-10-15 | 参天制药株式会社 | 由Rho激酶抑制剂和***素类物质构成的青光眼治疗剂 |
US8071779B2 (en) * | 2006-12-18 | 2011-12-06 | Inspire Pharmaceuticals, Inc. | Cytoskeletal active rho kinase inhibitor compounds, composition and use |
US20090325959A1 (en) * | 2008-06-26 | 2009-12-31 | Vittitow Jason L | Method for treating ophthalmic diseases using rho kinase inhibitor compounds |
-
2011
- 2011-07-15 JP JP2013520755A patent/JP2013531063A/ja not_active Withdrawn
- 2011-07-15 AU AU2011279909A patent/AU2011279909A1/en not_active Abandoned
- 2011-07-15 RU RU2013107007/04A patent/RU2013107007A/ru not_active Application Discontinuation
- 2011-07-15 KR KR1020137004048A patent/KR20130093093A/ko not_active Application Discontinuation
- 2011-07-15 WO PCT/US2011/044148 patent/WO2012012282A1/en active Application Filing
- 2011-07-15 EP EP11810195.5A patent/EP2595665A1/en not_active Withdrawn
- 2011-07-15 BR BR112013001125A patent/BR112013001125A2/pt not_active Application Discontinuation
- 2011-07-15 CA CA2805242A patent/CA2805242A1/en not_active Abandoned
- 2011-07-15 MX MX2013000664A patent/MX2013000664A/es not_active Application Discontinuation
- 2011-07-15 CN CN2011800355874A patent/CN103052406A/zh active Pending
-
2013
- 2013-01-15 US US13/742,073 patent/US20130131106A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2011279909A1 (en) | 2013-01-24 |
RU2013107007A (ru) | 2014-08-27 |
MX2013000664A (es) | 2013-03-07 |
US20130131106A1 (en) | 2013-05-23 |
CN103052406A (zh) | 2013-04-17 |
KR20130093093A (ko) | 2013-08-21 |
JP2013531063A (ja) | 2013-08-01 |
EP2595665A1 (en) | 2013-05-29 |
WO2012012282A1 (en) | 2012-01-26 |
CA2805242A1 (en) | 2012-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013001125A2 (pt) | compostos inibidores de rho cinase bifuncionais, composição e uso | |
BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
MX2021013110A (es) | Compuestos heterociclicos como inhibidores de la cinasa ret. | |
BR112015016315A2 (pt) | fluoro-[1,3]oxazinas como inibidores de bace1 | |
BRPI0712816B8 (pt) | compostos de pirrolpirimidina e seus usos | |
DOP2013000192A (es) | Compuestos y composiciones como inhibidores de la trk | |
BR112015021888A8 (pt) | inibidores de dna-pk, seus usos e composição farmacêutica | |
BR112014022106A2 (pt) | derivados macrocíclicos para o tratamento de doenças | |
BR112015023412A8 (pt) | 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante, sua composição farmacêutica e seu uso. | |
BR112012007102A2 (pt) | compostos policíclicos como antagonistas de receptores do ácido lisofosfatpidico | |
AU2011338389A8 (en) | Bicyclic compounds as Pim inhibitors | |
GT200800184A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes. | |
BR112014026643A8 (pt) | derivados de imidazotiadiazol e imidazopirazina como inibidores de receptor 4 ativado por protease (par4) para o tratamento de agregação de plaqueta, seus usos e composição farmacêutica | |
BR112012019765A2 (pt) | composto, e, uso de um composto. | |
BR112015022462A2 (pt) | inibidores de ido | |
MA32393B1 (fr) | Composés et compositions servant d'inhibiteurs de kinases | |
UY33597A (es) | Compuestos y composiciones como inhibidores de la trk | |
ECSP10010034A (es) | 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos | |
ECSP13013048A (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores | |
BR112013031098A2 (pt) | halogeno-alquil-1,3 oxazinas como inibidores de bace1 e/ou bace2 | |
BR112015019412A8 (pt) | inibidores de bace1, seus usos, e composição farmacêutica | |
BR112014015630A8 (pt) | fluorometil-5,6-di-hidro-4h-[1,3]oxazinas, seus usos, e composição farmacêutica | |
EA200802118A1 (ru) | Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях | |
EA201000130A1 (ru) | Бициклические гетероарильные соединения и их применение в качестве ингибиторов киназы | |
BR112012022650A2 (pt) | derivados de imidazo [1,2-a]pirazina e seu uso como inibidores de pde10 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |